Atria Wealth Solutions Inc. Boosts Stock Holdings in Zoetis Inc. (NYSE:ZTS)

Atria Wealth Solutions Inc. boosted its stake in Zoetis Inc. (NYSE:ZTSFree Report) by 0.4% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 15,975 shares of the company’s stock after purchasing an additional 70 shares during the quarter. Atria Wealth Solutions Inc.’s holdings in Zoetis were worth $2,779,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also bought and sold shares of the company. Quantinno Capital Management LP raised its stake in Zoetis by 2.6% in the second quarter. Quantinno Capital Management LP now owns 18,431 shares of the company’s stock valued at $3,174,000 after purchasing an additional 475 shares in the last quarter. FORVIS Wealth Advisors LLC raised its stake in Zoetis by 4.7% in the second quarter. FORVIS Wealth Advisors LLC now owns 1,350 shares of the company’s stock valued at $232,000 after purchasing an additional 61 shares in the last quarter. BLB&B Advisors LLC raised its stake in Zoetis by 1.9% in the third quarter. BLB&B Advisors LLC now owns 60,872 shares of the company’s stock valued at $10,591,000 after purchasing an additional 1,107 shares in the last quarter. Ronald Blue Trust Inc. raised its stake in Zoetis by 5.4% in the third quarter. Ronald Blue Trust Inc. now owns 6,216 shares of the company’s stock valued at $1,070,000 after purchasing an additional 317 shares in the last quarter. Finally, Advisor Partners II LLC raised its stake in Zoetis by 4.0% in the third quarter. Advisor Partners II LLC now owns 24,068 shares of the company’s stock valued at $4,187,000 after purchasing an additional 922 shares in the last quarter. 89.47% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research analysts have commented on ZTS shares. Piper Sandler lifted their price target on shares of Zoetis from $210.00 to $215.00 and gave the stock an “overweight” rating in a research note on Monday, November 6th. BNP Paribas started coverage on shares of Zoetis in a research note on Thursday, December 7th. They set an “outperform” rating and a $237.00 price target on the stock. The Goldman Sachs Group lifted their price target on shares of Zoetis from $190.00 to $226.00 and gave the stock a “buy” rating in a research note on Wednesday, January 17th. Stifel Nicolaus lifted their price target on shares of Zoetis from $195.00 to $215.00 and gave the stock a “buy” rating in a research note on Friday, January 12th. Finally, Jefferies Financial Group reissued a “buy” rating and set a $230.00 price target on shares of Zoetis in a research note on Tuesday, December 19th. Nine research analysts have rated the stock with a buy rating, According to MarketBeat.com, Zoetis currently has an average rating of “Buy” and a consensus price target of $223.78.

Get Our Latest Report on ZTS

Insider Transactions at Zoetis

In other news, CEO Kristin C. Peck sold 13,000 shares of the firm’s stock in a transaction that occurred on Tuesday, November 21st. The shares were sold at an average price of $176.84, for a total value of $2,298,920.00. Following the transaction, the chief executive officer now owns 56,843 shares in the company, valued at $10,052,116.12. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, EVP Roxanne Lagano sold 2,500 shares of Zoetis stock in a transaction on Thursday, December 14th. The shares were sold at an average price of $200.00, for a total value of $500,000.00. Following the sale, the executive vice president now owns 19,415 shares in the company, valued at $3,883,000. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Kristin C. Peck sold 13,000 shares of Zoetis stock in a transaction on Tuesday, November 21st. The shares were sold at an average price of $176.84, for a total transaction of $2,298,920.00. Following the completion of the sale, the chief executive officer now owns 56,843 shares in the company, valued at approximately $10,052,116.12. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 17,346 shares of company stock worth $3,139,405. Insiders own 0.12% of the company’s stock.

Zoetis Stock Up 0.8 %

Shares of Zoetis stock opened at $197.32 on Friday. The company has a debt-to-equity ratio of 1.29, a quick ratio of 2.16 and a current ratio of 3.87. Zoetis Inc. has a 52-week low of $151.03 and a 52-week high of $201.92. The stock has a market capitalization of $90.59 billion, a price-to-earnings ratio of 40.11, a P/E/G ratio of 2.87 and a beta of 0.88. The company’s 50 day moving average price is $192.81 and its 200-day moving average price is $183.12.

Zoetis Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 4th. Stockholders of record on Friday, April 19th will be issued a $0.432 dividend. This represents a $1.73 annualized dividend and a dividend yield of 0.88%. The ex-dividend date is Thursday, April 18th. Zoetis’s dividend payout ratio is 35.16%.

Zoetis Company Profile

(Free Report)

Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

Featured Stories

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.